Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML

Tools

Item Type:	Article
Title:	Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML
Creators Name:	Na, I.K., Kreuzer, K.A., Lupberger, J., Doerken, B. and Coutre, P.
Abstract:	The tyrosine kinase inhibitor imatinib inhibits the activity of the bcr/abl fusion protein present in patients with chronic myeloid leukemia. Although in chronic phase patients response to therapy can be monitored by quantitative RT-PCR for bcr/abl mRNA transcripts, in advanced disease (accelerated phase or blast crisis) only few patients respond on a molecular level. We investigated Wilms tumor gene (WT1) and bcr/abl mRNA transcripts in 16 accelerated phase CML patients by quantitative real time PCR. In contrast to the bcr/abl mRNA levels the WT1 mRNA levels were indicative for hematologic relapse (n = 6) versus response (n = 10).
Keywords:	Wilms Tumor Gene 1 (WT1), CML, Imatinib, Accelerated Phase, Quantitative RT-PCR
Source:	Leukemia Research Reports
ISSN:	2213-0489
Publisher:	Elsevier
Volume:	29
Number:	3
Page Range:	343-345
Date:	1 March 2005
Official Publication:	https://doi.org/10.1016/j.leukres.2004.08.003
PubMed:	View item in PubMed

Repository Staff Only: item control page